SK Biopharma kicks off Korea’s first 2020 IPO
SK Biopharmaceuticals has begun bookbuilding for its up to W959.3bn ($804.9m) IPO. It is set to be South Korea’s first listing in 2020.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: